A Phase II Study of Bevacizumab Alone or in Combination with TRC105 for Advanced Renal Cell Cancer
Phase of Trial: Phase II
Latest Information Update: 30 Aug 2018
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Carotuximab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 04 Sep 2017 Status changed from active, no longer recruiting to completed.
- 22 Aug 2017 Primary endpoint (PFS at 24 weeks) has not been met, according to results published in the Cancer.